Guggenheim Cuts Price Target on Tetraphase Pharma (TTPH) Following Disappointing cUTI Data.

Go back to Guggenheim Cuts Price Target on Tetraphase Pharma (TTPH) Following Disappointing cUTI Data.

Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI

September 8, 2015 4:01 PM EDT

Eravacycline Did Not Achieve Primary Endpoint in Pivotal Portion of cUTI Trial

Company to Host Conference Call at 4:30 p.m. ET Today

WATERTOWN, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) --... More

Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI

September 8, 2015 4:01 PM EDT

Eravacycline Did Not Achieve Primary Endpoint in Pivotal Portion of cUTI Trial

Company to Host Conference Call at 4:30 p.m. ET Today

WATERTOWN, Mass., Sept. 8, 2015 (GLOBE NEWSWIRE) --... More